Advocacy intelligence hub — real-time data for patient organizations
Janssen Research & Development, LLC — PHASE3
Janssen Research & Development, LLC — PHASE2
Eli Lilly and Company — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Epclusa
(sofosbuvir and velpatasvir)Orphan drugstandardGilead Sciences, Inc.
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
12.1 Mechanism of Action EPCLUSA is a fixed-dose combination of sofosbuvir and velpatasvir, which are direct-acting antiviral agents against the hepat...
MAVYRET
(glecaprevir and pibrentasvir)Orphan drugstandardAbbVie, Inc.
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
12.1 Mechanism of Action Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral ag...
Remicade
(infliximab)Orphan drugstandardJanssen Biotech, Inc.
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...